Published :
Tables : 42
Figures : 45
Category : Healthcare
No. of Pages : 245
Report Code : HC-1131
Insomnia Treatment Market Introduction Insomnia Treatment Market to value over USD 5.8 Billion by 2029 end and register a CAGR of over 5.2% from 2020 to 2029. The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth. With advancements in technology and invention of better, efficient, new therapies providing quick, positive results, the public is more open to accepting such cures. Thus the increase in the launch of novel products such as Merck & Co.’s Belsomra is projected to fuel high demand. Moreover, the availability of multiple generics is expected to boost the insomnia therapeutics market over the forecast period. Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is expected to be launched in the near future, which may promote growth. With new products and technology employed the market is estimated to soar unboundedly. Additionally, quite a few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favourable reimbursement policies and adoption of the device-drug combination therapies for treating insomnia. North America was leading the insomnia therapeutics market and accounted for a major revenue share. Favourable reimbursement policies will further promote revenue growth. North America is followed by the Asia Pacific, which is poised to grow at healthy CAGR. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives. Asia Pacific is anticipated to witness lucrative growth over the forecast period with a high CAGR. The global insomnia therapeutics market is highly fragmented with several manufacturers offering generics. Major market players are Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals; Merck & Co., Inc.,Pfizer Inc.; Teva Pharmaceutical Industries Ltd.,Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd, Sanofi, Paratek Pharmaceuticals Inc., Ebb Therapeutics . Insomnia Treatment Market Segmentation: By Drug Type • OTC Drugs • OTC Sleep Aids • OTC Sleep Supplements • Prescription Drugs By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • e-Commerce • Drug Stores • Others By Region: • Europe • North America • APAC • Latin America • Rest of World Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth Objectives of the Study: • To provide an exhaustive analysis on the global insomnia treatment market by drug type, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East. • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Insomnia Treatment Market to value over USD 5.8 Billion by 2029 end and register a CAGR of over 5.2% from 2020 to 2029.
The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth.
With advancements in technology and invention of better, efficient, new therapies providing quick, positive results, the public is more open to accepting such cures. Thus the increase in the launch of novel products such as Merck & Co.’s Belsomra is projected to fuel high demand. Moreover, the availability of multiple generics is expected to boost the insomnia therapeutics market over the forecast period. Lemborexant, a novel Orexin Receptor Antagonist (ORA) by Eisai is expected to be launched in the near future, which may promote growth. With new products and technology employed the market is estimated to soar unboundedly. Additionally, quite a few medical devices have been approved in the recent years such as EBB Insomnia Therapy, Fisher Wallace Stimulator, and Alpha-Stim AID, which are expected to have higher penetration due to favourable reimbursement policies and adoption of the device-drug combination therapies for treating insomnia.
North America was leading the insomnia therapeutics market and accounted for a major revenue share. Favourable reimbursement policies will further promote revenue growth. North America is followed by the Asia Pacific, which is poised to grow at healthy CAGR. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives. Asia Pacific is anticipated to witness lucrative growth over the forecast period with a high CAGR.
The global insomnia therapeutics market is highly fragmented with several manufacturers offering generics.
Major market players are Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals; Merck & Co., Inc.,Pfizer Inc.; Teva Pharmaceutical Industries Ltd.,Mylan N.V., Sumitomo Dainippon Pharma Co., Ltd, Sanofi, Paratek Pharmaceuticals Inc., Ebb Therapeutics .
Insomnia Treatment Market Segmentation:
By Drug Type • OTC Drugs • OTC Sleep Aids • OTC Sleep Supplements • Prescription Drugs
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • e-Commerce • Drug Stores • Others
By Region: • Europe • North America • APAC • Latin America • Rest of World
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data points affecting market growth
Objectives of the Study: • To provide an exhaustive analysis on the global insomnia treatment market by drug type, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East. • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Insomnia Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Insomnia Treatment Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Insomnia Treatment on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Insomnia Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Insomnia Treatment Market, By Drug Type Historical Analysis and Forecast 2020-2029 (USD Million) 7.1. OTC Drugs 7.2. OTC Sleep Aids 7.3. OTC Sleep Supplements 7.4. Prescription Drugs 8. Global Insomnia Treatment Market, By Distribution Channel Historical Analysis and Forecast 2020-2029 (USD Million) 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. e-Commerce 8.4. Drug Stores 8.5. Others 9. North America Market Analysis 2012–2019 and Forecast 2020–2029 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2013-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2020-2029 10. Latin America Market Analysis 2013–2020 and Forecast 2020–2029 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2013-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2020-2029 11. Europe Market Analysis 2013–2020 and Forecast 2020–2029 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2013-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2020-2029 12. Asia Pacific Market Analysis 2013–2020 and Forecast 2020–2029 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2013-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2029 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2020–2029 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2020-2029 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Takeda Pharmaceutical Company Ltd. 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Vanda Pharmaceuticals 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Merck & Co.Inc. 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Pfizer Inc. 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Teva Pharmaceutical Industries Ltd. 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Mylan N.V. 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Sumitomo Dainippon Pharma Co. Ltd. 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Sanofi 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Paratek Pharmaceuticals Inc. 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10.Ebb Therapeutics 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 14.11. Sonafi 14.11.1. Company Overview 14.11.2. Product Portfolio 14.11.3. SWOT Analysis 14.11.4. Financial Overview 14.11.5. Strategic Overview 15. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics